Biomarker-supported Alzheimer's disease (abnormal CSF p-tau/Aβ42 ratio of \> 0.023 or amyloid PET positive).
Between 50 and 85 years old.
Clinical Dementia Rating (CDR) score of 0.5 or 1.
Mini-Mental State Examination (MMSE) score between 18 and 27.
Presence of a caregiver.
You may not be if
Medical history of neurodegenerative diseases other than AD, stroke, or epilepsy.
Severe psychiatric dysregulation, hampering successful study participation and leading to possible cognitive impairment. Eligibility for participation will be based on clinical evaluation by an expert neurologist and/or psychiatrist.
Extensive cerebrovascular damage on MRI classified as Fazekas level 2 or 3. Patients with abnormalities classified as Fazekas level 3 are excluded. For Fazekas level 2, patient's eligibility for participation will be evaluated by an expert neurologist.
Presence of metal in the head or cranial/thoracic implants, including cochlear implants.
Cholinesterase inhibitors with unstable dosage in the last 2 months.
Extreme claustrophobia or metallic objects in or on the body, preventing MRI and MEG examination.
